We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Moderna announced this week that its coronavirus vaccine, mRNA-1273, appears to not only be more effective than Pfizer’s candidate but has significantly less stringent temperature requirements as well, likely making distribution and storage of the vaccine an easier, less daunting task. Read More
Inovio has launched the phase 2 portion of its phase 2/3 clinical trial evaluating INO-4800, a potential coronavirus vaccine funded by the Department of Defense (DoD). Read More
Indivior Solutions, the maker of suboxone — a drug approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment for opioid-use disorder — was sentenced last week to pay $289 million in criminal penalties for unlawful marketing of an opioid drug. Read More
The HHS Office of Inspector General (OIG) has issued a warning to drugmakers to avoid paying kickbacks in the form of payments for speaker programs. Read More
Companies that have developed a COVID-19 vaccine that is approved in the European Union will have to submit monthly safety reports during the pandemic to the European Medicines Agency (EMA), the agency said. Read More
Hacker groups in Russia and North Korea have continue to wage cyberattacks against companies working on COVID-19 vaccines and treatments, Microsoft warned Monday, calling on governments to take action against them. Read More
A new survey shows one in five cancer patients are far less likely to participate in future clinical trials due to fear of COVID-19 exposure, raising the question of whether enrollment levels that have dropped precipitously since the beginning of the pandemic are likely to recover after the virus is controlled. Read More
President Trump said Friday that his administration is “working to secure an Emergency Use Authorization” from the FDA for Pfizer’s vaccine candidate for COVID-19 and that it will be available to the general population for free “as soon as April,” but will be withheld from states like New York whose governors have expressed qualms about a vaccine approved by the FDA under the current administration. Read More
Despite the FDA’s recent approval, international skepticism persists over the use of Gilead Sciences’ remdesivir for treating COVID-19 patients. Another prominent group, the European Society of Intensive Care Medicine, is now advising clinicians that the drug should not be routinely used for treating COVID-19 patients Read More